Interleukin-10 Promotes Pathological Angiogenesis by Regulating Macrophage Response to Hypoxia during Development

被引:120
作者
Dace, Dru S. [1 ]
Khan, Aslam A. [1 ]
Kelly, Jennifer [1 ]
Apte, Rajendra S. [1 ,2 ]
机构
[1] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Dev Biol Program, St Louis, MO 63130 USA
来源
PLOS ONE | 2008年 / 3卷 / 10期
关键词
D O I
10.1371/journal.pone.0003381
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Aberrant angiogenesis in the eye is the most common cause of blindness. The current study examined the role of interleukin-10 (IL-10) in ischemia-induced pathological angiogenesis called neovascularization during postnatal development. IL-10 deficiency resulted in significantly reduced pathological retinal angiogenesis. In contrast to the choroicapillaris where IL-10 interferes with macrophage influx, IL-10 did not prevent anti-angiogenic macrophages from migrating to the retina in response to hypoxia. Instead, IL-10 promoted retinal angiogenesis by altering macrophage angiogenic function, as macrophages from wild-type mice demonstrated increased vascular endothelial growth factor (VEGF) and nitric oxide (NO) compared to IL-10 deficient macrophages. IL-10 appears to directly affect macrophage responsiveness to hypoxia, as macrophages responded to hypoxia with increased levels of IL-10 and STAT3 phosphorylation as opposed to IL-10 deficient macrophages. Also, IL-10 deficient macrophages inhibited the proliferation of vascular endothelial cells in response to hypoxia while wild-type macrophages failed to do so. These findings suggest that hypoxia guides macrophage behavior to a pro-angiogenic phenotype via IL-10 activated pathways.
引用
收藏
页数:10
相关论文
共 41 条
[1]   Immunological mechanisms in the pathogenesis of diahetic retinopathy [J].
Adamis, Anthony P. ;
Berman, Adrienne J. .
SEMINARS IN IMMUNOPATHOLOGY, 2008, 30 (02) :65-84
[2]   SUPPRESSION OF RETINAL NEOVASCULARIZATION IN-VIVO BY INHIBITION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) USING SOLUBLE VEGF-RECEPTOR CHIMERIC PROTEINS [J].
AIELLO, LP ;
PIERCE, EA ;
FOLEY, ED ;
TAKAGI, H ;
CHEN, H ;
RIDDLE, L ;
FERRARA, N ;
KING, GL ;
SMITH, LEH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) :10457-10461
[3]   Nitric oxide is proangiogenic in the retina and choroid [J].
Ando, A ;
Yang, A ;
Mori, K ;
Yamada, H ;
Yamada, E ;
Takahashi, K ;
Saikia, J ;
Kim, M ;
Melia, M ;
Fishman, M ;
Huang, P ;
Campochiaro, PA .
JOURNAL OF CELLULAR PHYSIOLOGY, 2002, 191 (01) :116-124
[4]   Macrophages inhibit neovascularization in a murine model of age-related macular degeneration [J].
Apte, Rajendra S. ;
Richter, Jennifer ;
Herndon, John ;
Ferguson, Thomas A. .
PLOS MEDICINE, 2006, 3 (08) :1371-1381
[5]   Development of proliferative diabetic retinopathy in African-Americans and whites with type 1 diabetes [J].
Arfken, CL ;
Reno, PL ;
Santiago, JV ;
Klein, R .
DIABETES CARE, 1998, 21 (05) :792-795
[6]   VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) GENE IS EXPRESSED DIFFERENTIALLY IN NORMAL-TISSUES, MACROPHAGES, AND TUMORS [J].
BERSE, B ;
BROWN, LF ;
VANDEWATER, L ;
DVORAK, HF ;
SENGER, DR .
MOLECULAR BIOLOGY OF THE CELL, 1992, 3 (02) :211-220
[7]   Interleukin (IL)-6, interleukin (IL)-8 levels and cellular composition of the vitreous humor in proliferative diabetic retinopathy, proliferative vitreoretinopathy, and traumatic proliferative vitreoretinopathy [J].
Canataroglu, H ;
Varinli, I ;
Ozcan, AA ;
Canataroglu, A ;
Doran, F ;
Varinli, S .
OCULAR IMMUNOLOGY AND INFLAMMATION, 2005, 13 (05) :375-381
[8]   Nitric oxide in excitable tissues: Physiological roles and disease [J].
Christopherson, KS ;
Bredt, DS .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (10) :2424-2429
[9]  
Davies M, 2006, MOL VIS, V12, P467
[10]   MACROPHAGES IN PROLIFERATIVE VITREORETINOPATHY AND PROLIFERATIVE DIABETIC-RETINOPATHY - DIFFERENTIATION OF SUBPOPULATIONS [J].
ESSER, P ;
HEIMANN, K ;
WIEDEMANN, P .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1993, 77 (11) :731-733